DURECT Corporation (DRRX)
Chart Events
Performance Outlook
| Previous Close | 6.40 |
| Open | 5.81 |
| Bid | 5.72 x 1100 |
| Ask | 5.90 x 800 |
| Day's Range | 5.70 - 6.28 |
| 52 Week Range | 3.17 - 9.70 |
| Volume | |
| Avg. Volume | 65,546 |
| Market Cap | 132.159M |
| Beta (5Y Monthly) | 1.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.00 |
| Earnings Date | Mar 06, 2023 - Mar 10, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.33 |
- PR Newswire
DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants
DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has entered into a definitive agreement with a leading institutional healthcare investor and an existing institutional investor for the purchase and sale of an aggregate of 1,700,000 shares of common stock and, in lieu of shares of common stock, pre-funded warrants to purchase 3
- Zacks
Durect (DRRX) Soars 11.8%: Is Further Upside Left in the Stock?
Durect (DRRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- PR Newswire
DURECT Announces 1-for-10 Reverse Stock Split
DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, announced that DURECT's board of directors today determined that the Company will effect a reverse stock split at a ratio of 1-for-10 as of 5:01 p.m. Eastern Time on December 5, 2022. Beginning with the opening of trading on December 6, 2022, the Company's common stock will trade on a split-adjusted basis.
